ArticleTherapeutic advances in gastroenterology2023

Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.

Piotr Eder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.